Many younger patients with stomach cancer have a distinct disease, Mayo research discovers
Mayo Clinic researchers discovered that many people younger than 60 who develop gastric cancer have a genetically distinct form of... Read More
Our Impact
Gastric Cancer Foundation improves the lives of people affected by gastric (stomach) cancer by supporting patient education initiatives and innovative research studies to improve treatments and ultimately, find a cure.
Support Research for a Cure
Every contribution to Gastric Cancer Foundation makes a difference. Honor a loved one, make a tribute to someone’s memory, honor a happy occasion by making a meaningful donation.
-
Treatment Efficacy in Metastatic Esophageal, Gastric, or Gastroesophageal Cancer According to Expression of ERCC1
The biomarker ERCC1 is of interest for predicting sensitivity to platinum-based chemo, but a recent study in the Journal of... Read More
Gastric Cancer Foundation Funds Important New Stomach Cancer Research
The Gastric Cancer Foundation recently announced a new $75,000 research grant to The University of Texas MD Anderson Cancer Center.... Read More
Gastric Cancer Foundation Sponsors Online Forum for Patients & Family Members
You are not alone. Gastric Cancer Foundation helps connects patients and family members to people who are on a similar... Read More
Gastric Cancer Susceptability Marker Discovered
An international team of researchers discovered that a deficiency in factor USF1, coupled with low levels of the protein p53,... Read More
Meat intake and risk of gastric cancer in the Stomach cancer Pooling (StoP) Project
Researchers analyzed 22 studies involving more than 11,000 gastric cancer patients and determined that the consumption of red and processed... Read More
Curbing Cancer’s Addiction to Treat It
In a new study, Australian researchers describe how they stopped gastric cancer growth in lab models by neutralizing a gene... Read More
Japanese firm’s AI algorithm for gastric cancer gets FDA’s Breakthrough Device designation
Tokyo-based AI Medical Service won breakthrough device designation from the FDA for its technology that uses machine learning to identify... Read MoreDecember 2019 Newsletter
Our Gastric Cancer Foundation Newsletter: December 2019 features a special message from Foundation Board Chair, Paul Gottsegen.
H. Pylori Infection Must Be Wiped Out to Cut Gastric Cancer Risk
A new study led by UPenn’s Perelman school shows that completely eradicating H. Pylori infection reduces the risk of gastric... Read More
Novel, high-accuracy blood test can screen for multiple cancers
An investigational blood test for cancer was able to identify early-stage tumors, including gastric cancer, with high accuracy, according to... Read More
Pfizer, Merck KGaA’s Bavencio flunks study in hard-to-treat gastric cancer
The PD-L1 inhibitor Bavencio did not outperform chemo at extending patients’ lives in a major study in gastric cancer, raising... Read More
Scientific American: What We Know about the Possible Carcinogen Found in Zantac
Concerned by the news that the widely used heartburn medication Zantac (ranitidine) was recalled due to a finding of a... Read More
Relationship between long-term use of proton pump inhibitors and risk of gastric cancer: A systematic analysis
A recent study of users of proton pump inhibitors to treat heartburn found that use of the drugs for 36... Read More
Imugene welcomes receipt of US Department of Defense grant for City of Hope cancer researchers
City of Hope has received a $564,000 grant from the Department of Defense to study a cancer-fighting virus in the... Read More
Foundation-Funded Research Scholar Receives NIH Grant to Continue Research
Jose Saenz, the 2017 recipient of the AGA–Gastric Cancer Foundation Ben Feinstein Memorial Research Scholar Award in Gastric Cancer, has... Read More
Cancer patients who exercise have less heart damage from chemotherapy
A paper published by the European Journal of Preventative Cardiology reports that cancer patients who exercise have less heart damage... Read More
Elevar Announces Results from the Angel Trial, A Study of Monotherapy Rivoceranib (Apatinib) In Late-Stage Gastric Cancer Patients
At ESMO 2019, Elevar Therapeutics announced that in a phase 3 trial in gastric cancer patients, rivoceranib did not improve... Read More
Survival Outcomes of Gastric and Gastroesophageal Junction Adenocarcinomas Treated With Perioperative Chemotherapy ± Preoperative Radiotherapy
A new study of patients with early- and mid-stage gastric cancer found that those treated with chemo and radiation before... Read More-
Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy
A study of the new drug Lonsurf in gastric cancer found that the treatment was tolerable and improved overall survival... Read More
Monthly Newsletter
We’ll deliver our monthly newsletter to your Inbox with Foundation updates, news about cutting edge research and trends in the field, and how to make a difference.